Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Protalix BioTherapeutics stock has a target of 12, which predicts a 455.56% increase from the current stock price of 2.16.

Price Target: $12 (+455.56%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$12	$12	$12	$12
Change	+455.56%	+455.56%	+455.56%	+455.56%

* Price targets were last updated on Mar 19, 2026.

Analyst Ratings

According to 1 stock analyst, the rating for Protalix BioTherapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26
Strong Buy	1	1	1	1	1	1
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	1	1	1	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $12	Strong Buy	Reiterates	$12	+455.56%	Mar 19, 2026
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $15 → $12	Strong Buy	Maintains	$15 → $12	+455.56%	Nov 21, 2025
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $10 → $15	Strong Buy	Maintains	$10 → $15	+594.44%	Feb 3, 2025
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $10	Strong Buy	Reiterates	$10	+362.96%	Nov 14, 2023
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $7 → $10	Strong Buy	Maintains	$7 → $10	+362.96%	Oct 31, 2023

More Analyst Ratings

Financial Forecast

Revenue This Year

72.16M

Increased by 36.81%

from 52.74M

Revenue Next Year

69.73M

Decreased by -3.36%

from 72.16M

EPS This Year

0.07

from -0.08

EPS Next Year

0.11

Increased by 57.14%

from 0.07

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	38.35M	47.64M	65.49M	53.40M	52.74M	72.16M	69.73M
Revenue Growth	-39.03%	24.22%	37.48%	-18.47%	-1.23%	36.81%	-3.36%
EPS	-0.62	-0.31	0.09	0.04	-0.08	0.07	0.11
EPS Growth	-	-	-	-57.71%	-	-	57.14%
Forward PE	-	-	-	-	-	30.55	19.44
No. Analysts	-	-	-	-	-	3	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	82.4M	79.9M
Avg	72.2M	69.7M
Low	63.2M	60.7M

Revenue Growth

Revenue Growth	2026	2027
High	56.2%	10.7%
Avg	36.8%	-3.4%
Low	19.8%	-15.8%

EPS Forecast

EPS	2026	2027
High	0.21	0.15
Avg	0.07	0.11
Low	-0.06	0.08

EPS Growth

EPS Growth	2026	2027
High	-	107.9%
Avg	-	57.1%
Low	-	10.9%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.